Drug Profile
Research programme: monoclonal antibodies - Lanier Biotherapeutics
Latest Information Update: 07 Oct 2021
Price :
$50
*
At a glance
- Originator Abeome Corporation
- Developer Cato Research; Lanier Biotherapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 05 Oct 2021 Biophtha has merged with Abeome Corporation to form Lanier Biotherapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (IV)
- 14 Apr 2011 Preclinical development is ongoing in USA